Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Uliledlimab by I-Mab for Ovarian Cancer: Likelihood of Approval
Uliledlimab is under clinical development by I-Mab and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of I-Mab's Lemzoparlimab?
Lemzoparlimab is a monoclonal antibody commercialized by I-Mab, with a leading Phase II program in Primary Mediastinal B-Cell Lymphoma. According...
Risk adjusted net present value: What is the current valuation of I-Mab's Uliledlimab?
Uliledlimab is a monoclonal antibody commercialized by I-Mab, with a leading Phase II program in Oropharyngeal Cancer. According to Globaldata,...
Givastomig by I-Mab for Solid Tumor: Likelihood of Approval
Givastomig is under clinical development by I-Mab and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Givastomig by I-Mab for Gastric Cancer: Likelihood of Approval
Givastomig is under clinical development by I-Mab and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...